← Insider buys

STXS

Stereotaxis, Inc. · Healthcare

Insiders bought $67K of Stereotaxis, Inc. in the last 12 months

1 insider bought on 1 day.

$67KBought, 12 mo
$0Sold, 12 mo
$102.2MMarket cap

STXS over the last year

Insider buy filed (1 day)

Largest buyers, last 12 months

STXS after insider buys

3 months after each buy, from the first price a copier could get.

+9.3%Average
+3.5 ptsVs S&P 500
3 of 5Higher

5 buys since 2022 with 3 months of prices.

Every filing

29 insider filings since 2020, newest first

About Stereotaxis, Inc.

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Navigation by reducing the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a Synchrony and SynX Solution offer integrated, real-time information solution to manage, control, record and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including MAGiC catheter, a robotically navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures; MAGiC Sweep, a mapping catheter; QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; and V-CAS devices. Further, it provides interventional devices under the Map-iT, MAGiC, and EMAGIN brands, and other related devices. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.